Study S003280

An Open-label, Randomized, Multiple-dose, Two-cycle, Two-way Crossover Phase 1 Study to Evaluate the Effect of Food on the Pharmacokinetics of CX11 Tablets in Healthy Participants

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07349381
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 32
Start: 2026-03-04
Primary completion: 2026-06-30
Lead sponsor: Vincentage Pharma Co., Ltd
Conditions: Obesity & Overweight; Type 2 Diabetes
Interventions: DRUG:CX11 (VCT220)
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Area Under the Concentration-time curve from 0 to 24 hour (AUC0-24) of CX11 (VCT220) [Predose at Day1 up to 35 days postdose]
Maximum Observed Concentration (Cmax) of CX11 (VCT220) [Predose at Day1 up to 35 days postdose]
Time to Maximum Observed Concentration (Tmax) of CX11 (VCT220) [Predose at Day 1 up to 35 days postdose]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.